Literature DB >> 17046987

Improving patient outcomes in schizophrenia: achieving remission.

Henry A Nasrallah1, Rob Lasser.   

Abstract

The Remission in Schizophrenia Working Group has recently proposed a consensus definition of remission in schizophrenia and, based on this definition, has developed specific operational criteria for the assessment of remission. The aim of this article was to assess the application of these consensus criteria and to discuss the barriers for achieving remission. An electronic literature search of studies published between January 1990 and December 2005 examining the concepts of remission, compliance and patient satisfaction in schizophrenia was performed using Medline and EMBASE. The primary research parameters were 'schizophrenia', 'remission', 'antipsychotics', 'atypicals' and 'conventional'. Abstracts and posters presented at key psychiatry congresses during this period were also reviewed, where available in the public domain. To date, the remission criteria have been applied retrospectively to a number of clinical studies, and these have demonstrated that the proposed definition of remission correlates significantly with established measures of symptom severity, functioning and quality of life, and appears achievable and sustainable for a significant proportion of patients receiving pharmacotherapy. The atypical antipsychotic agents have been shown to impact favourably upon certain factors that play an integral part in the achievement of remission, such as negative symptoms, cognitive impairment, social functioning and quality of life. However, non-compliance with medication remains widespread due to illness-, treatment- and clinician-related factors. The use of long-acting antipsychotic agents, with their assured medication delivery, may facilitate compliance and improve long-term treatment outcomes, possibly assisting patients in achieving remission. Remission may, therefore, be considered as a current goal of treatment today, not a distant future aim.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046987     DOI: 10.1177/1359786806071248

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  23 in total

1.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

2.  What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Ilja Spellmann; Richard Musil; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

3.  Remission and recovery during the first outpatient year of the early course of schizophrenia.

Authors:  Joseph Ventura; Kenneth L Subotnik; Lisa H Guzik; Gerhard S Hellemann; Michael J Gitlin; Rachel C Wood; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2011-07-18       Impact factor: 4.939

4.  A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.

Authors:  Wayne Macfadden; Yi-Wen Ma; J Thomas Haskins; Cynthia A Bossie; Larry Alphs
Journal:  Psychiatry (Edgmont)       Date:  2010-11

5.  Physical and mental health-related quality of life among older people with schizophrenia.

Authors:  David P Folsom; Colin Depp; Barton W Palmer; Brent T Mausbach; Shahrokh Golshan; Ian Fellows; Veronica Cardenas; Thomas L Patterson; Helena C Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2009-01-24       Impact factor: 4.939

Review 6.  Schizophrenia outcomes in the 21st century: A systematic review.

Authors:  Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner
Journal:  Brain Behav       Date:  2021-05-15       Impact factor: 2.708

Review 7.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

8.  A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Authors:  Danielle Coppola; Yanning Liu; Srihari Gopal; Bart Remmerie; Mahesh N Samtani; David W Hough; Isaac Nuamah; Ahmad Sulaiman; Gahan Pandina
Journal:  BMC Psychiatry       Date:  2012-03-28       Impact factor: 3.630

9.  Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.

Authors:  Virginia Stauffer; Haya Ascher-Svanum; Lin Liu; Tamara Ball; Robert Conley
Journal:  BMC Psychiatry       Date:  2009-03-31       Impact factor: 3.630

10.  Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.

Authors:  Federica Pinna; Andrea Fiorillo; Massimo Tusconi; Beatrice Guiso; Bernardo Carpiniello
Journal:  Int J Ment Health Syst       Date:  2015-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.